Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MEI Pharma to Consider Strategic Alternatives
Raiders took all the cash with the dividend.Now the company share price is tanking,with no soft landing.No revenue streams and coffers are empty.Very difficult too see a bright future,here.All these trials take time and money.We will need an infusion of cash soon.Good luck and good trading.
Pretty stagnant on this board for awhile ..Could be a good sign?
only 2 ask size 100 shares...
no selling all holding.
Out. May recover but R/S concern is here. Flip but still watching. Usually don't say much but since I told you I got some, figured I should.
MEIP
Doing a little. Risking a part of prior trades. Got only 1500 on that mini dip but didn't hit my larger .23 bid.
MEIP
What’s your take on Today thinking if loading
Lead drug. FDA issue. Continuing trails in Japan with partner. Has cash to continue with two other drugs here.
MEIP
Why did it drop so much
Bidding now. A little below current bid.
MEIP
Good move Friday $$$
MEIP
Who the fuck is selling all those shares.... institutions?
Little flips add up.
MEIP
Again.
MEIP
MEIP - MEI Pharma, Inc. (NASDAQ:MEIP) Shares Purchased by Sigma Planning Corp
Sigma Planning Corp lifted its holdings in MEI Pharma, Inc. (NASDAQ:MEIP – Get Rating) by 164.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 418,950 shares of the company’s stock after purchasing an additional 260,600 shares during the quarter. Sigma Planning Corp owned about 0.32% of MEI Pharma worth $252,000 as of its most recent SEC filing.
https://www.defenseworld.net/2022/07/11/mei-pharma-inc-nasdaqmeip-shares-purchased-by-sigma-planning-corp.html
I had a buddy tell me to buy this. Bought at .52. Completely forgot about it. What's up with the move?
Nice move.
MEIP
Keeps going up.
MEIP
Another nice move. Buy some, sell some, hold some.
MEIP
Dip but .51 not filled
MEIP
Premarket volume.
meip
Premarket volume.
meip
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
https://marketwirenews.com/news-releases/mei-pharma-and-kyowa-kirin-report-new-clinical-data--7831482843146987.html?t=389791
Again.
MEIP
Another nice bounce.
MEIP
Decent move..
MEIP
Very nice. Can MEIP breakout?
Bouncing off new low.
MEIP
Nice little run..
MEIP
Nice move. Occasionally lucky. Bought yesterday.
MEIP
But there may be hope after avg down
MEI Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $5.44, representing an 859.9% upside.
Very very poorly
Well, How your 98s work out?
Glutton for punishment.. back in @.537 average..
Out @.589, lol that was quick.. i’ll keep an eye on it and jump back in when the timing is right..
Took a new position on MEIP, 50k @.593 average.
MEIP MEIP roadrunner goes off the cliff.
The price is better
Ouch, 25% loss in less than a day - Guess .98 wasn't the right entry point last night.
Well, Let's see how my .98s work out going forward from here.
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1397
|
Created
|
11/05/12
|
Type
|
Free
|
Moderators |
MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.
http://www.meipharma.com/our-programs/pracinostat
In August 2016, we announced that the U.S. Food & Drug Administration granted Breakthrough Therapy Designation for Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Later that month, we entered into an exclusive licensing, development and commercialization agreement with Helsinn Healthcare, SA, a Swiss pharmaceutical corporation, for Pracinostat in AML and other potential indications, including MDS.
http://www.meipharma.com/our-programs/me-401
ME-401 is a potent and selective oral inhibitor of PI3K delta, a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells. Results from a first-in-human, single ascending dose clinical study suggest that ME-401 has the potential for an improved therapeutic window compared to other PI3K delta inhibitors, with a half-life that supports once-daily dosing. A Phase Ib dose-escalation study of ME-401 in patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (fNHL) opened for enrollment in September 2016.
http://www.meipharma.com/our-programs/me-344
ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. Results from a Phase I clinical study of ME-344 in patients with refractory solid tumors showed evidence of clinical activity, including a confirmed partial response in a heavily pre-treated patient with small cell lung cancer who remained on study for two years. An investigator-sponsored study of ME-344 in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in HER2-negative breast cancer opened for enrollment in August 2016.
MEI Pharma is listed on the Nasdaq Capital Market (Nasdaq: MEIP).
Financial Highlights as of September 30, 2016
- $58.9 million in cash
- No debt
- 36.8 million shares outstanding
Company website:
http://www.meipharma.com
Company presentation:
http://www.meipharma.com/sites/default/files/meip_presentation_-_stifel_nov_2016_-_final_2_0.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |